Alterations in cell surface carbohydrate expression during neoplastic development have been frequently observed in man and animals (Feizi, 1985a; Feizi, 1985b; Hakomori, 1989; Smets & Van Beek, 1984; Yogeeswaran, 1983) . This seems to hold true for mammary neoplasia (Franklin, 1983; Gooi et al., 1985a; Gooi et al., 1985b; Howard et al., 1981; McKenzie & Xing, 1990; Muller-Holzner et al., 1985; Taylor-Papadimitriou et al., 1990) . The role of transformation events, such as carcinogen treatment (Russo et al., 1988) or oncogene activation (Bolsher et al., 1988; Rak et al., 1991) , in cell surface carbohydrate alterations have been proposed. Despite the wealth of information on tumour associated carbohydrate structures it is unclear whether multiple sequential genetic and phenotypic alterations driving tumour progression (Chen et al., 1989 and references therein) are paralleled by a particular sequence of changes in cell glycosylation patterns. On the other hand, the expression of certain carbohydrates seems to be associated with differentiation of cell components of the normal mammary gland (Rudland, 1987; Rudland et al., 1989) . In particular, differential binding of Peanut agglutinin (PNA) to mammary cell subsets such as alveolar, ductal, myoepithelial, and stromal cells was reported in both human and rat systems (Rudland, 1987; Newman et al., 1979) . In our experience, also, murine epithelium but not stroma is rich in PNA binding sites. We wished to determine whether PNA binding characteristics are a function of mammary tumour progression for two reasons. Firstly, knowing that high PNA binding is a differentiation marker of some, but not all cells in the mammary gland we were curious whether this feature is lost or amplified during development of the neoplasia. In any case this could be a result of eithuer clonal expansion of cells expressing a particular 'normal' PNA binding phenotype or expression of an 'abnormal' phenotype at the cellular level. Secondly, we were interested in the possible relationship between the expression of PNA reactive glycoconjugates and growth rate, tumorigenicity, metastatic potential and other biological characteristics of transformed mammary cells. Instead of examining paired normal vs malignant or metastatic vs non-metastatic cell types, we decided to analyse the full spectrum of progression from normal mammary epithelium to benign hyperplasia to neoplasia including resulting tumour cell heterogeneity. In this study we compared murine mammary cells at different stages of progression with respect to PNA binding intensity to the cell surface using flow cytometry and analysed expression of PNA reactive glycoproteins by SDS-PAGE.
Materials and methods

Tumours
The preneoplastic mammary hyperplastic alveolar nodule line D2HAN (Medina, 1973) (Mahoney et al., 1985 A series of sister cell populations derived from a single spontaneous BALB/cfC3H mouse mammary tumour (Dexter et al., 1978; Miller et al., 1986) , lines 66c14, 67, 68H, 4T07, 44FTO, and 168FARN, express different phenotypes with respect to in vivo and in vitro growth and metastasis. Line 64PT is a hybrid of 4TO7 and 68H (Miller et al., 1988b) . SPI(MIMl) is a metastatic variant of the SPI spontaneous CBA/J mammary adenocarcinoma (Elliott et al., 1988) obtained from Dr Bruce Elliott, Queens University, Kingston, Ontario.
Tumour cells were grown in DME supplemented with 5% fetal bovine serum (FBS), 5% calf serum (CS), 2 mM glutamine, 100 U ml-' penicillin, 100 jig ml-' streptomycin and 1 mM of mixed nonessential amino acids. Culturing of tumour cells in media used for mammary epithelium and D2HAN (see below) did not alter any of their properties.
Primary cell culture
Tumours were dissociated mechanically and by treatment with Collagenase type 3 (Worthington) 2 mg ml-' and Hyaluronidase (Sigma) 1 mg ml-' for 1 h on ice with subsequent repetitive agitation for 30 s in a Stomacher Blender (Miller et al., 1990) . Normal mammary cell cultures were prepared using the procedure described elsewhere (Miller & McInerney, 1988 The procedulre was described previously (Rak et al., 1991) . Briefly, cells were harvested with trypsin-EDTA solution, incubated in DME-IOFBS for 1 h on ice, washed, pelleted, and incubated for 40 min with 10-50 ,lg ml1' (usually 25 ;tg ml-') of fluorescent Peanut lectin (PNA-FITC), Soy bean agglutinin (SBA), or Griffonia simplicifolia isolectin (GSIB4) in the presence (control) or absence of an appropriate blocking sugar (galactose, N-Acetylo-galactosamine, or alpha-methyl galactopyranoside, respectively). All the lectin blocking sugars were purchased from Sigma Chemical Co. (St Louis, MO) . In some experiments, prior to incubation with lectins, cells were treated with 0.1 U ml-' neuraminidase (type V, Cl. perfringens, Sigma Chemical Co., St Louis, MO). After several washes, cells were fixed in 0.1% paraformaldehyde and analysed by FACStar flow cytometer under 420 nm of Innova 90 Argon laser light (Becton Dickinson, Mountain View, CA). Mean specific fluorescence intensity was calculated by subtraction of the mean fluorescence intensity of cells incubated with sugar-inactivated lectin from the mean fluorescence of cells stained with intact lectin. Significance of differences was confirmed at the confidence level of P <0.001 according to Kolmogorow-Smirnow statistics. Some variability in modal fluorescence between different stainings of the same cell population was seen. This was a result of different batches and, in some cases, concentrations of the fluorescent lectins used in individual experiments. Also setting of the instrument for each individual analysis might have been a source of some variability of the numerical values describing fluorescence intensity. Parallel fluctuations of those values were seen in control samples and between different cell types, so they did not affect the results. We also noticed that in the case of clonal D2 tumour cell lines untreated with neuraminidase (D2.OR, D2.1, D2A1) the staining intensity is up to 30% lower when the cells remain confluent as compared to the cells in the log phase of growth. Although the cells were always analysed at approximately the same (70-90%) confluency some fluorescence fluctuations may be due to this phenomenon. The latter, however, did not obscure several fold relative differences between the cell lines. Also, size and direction of the confluency dependent shift was similar for all of the three clonal D2 tumour cell lines. The time course and nature of this confluence-related shift in expression of PNA binding sites was not examined in detail. Double staining with propidium iodide and PNA-FITC did not suggest any S-phase specific expression of the lectin binding sites for any of these lines.
PNA overlays Semiconfluent cell cultures were harvested with 2 mM EDTA, washed in PBS, pelleted, and treated with lysis buffer containing 0.5% NP-40, 1 mM EDTA, and 1 mM phenylmethylsulfonylfluoride in PBS. The protein equivalent of 3 x 106 cells was separated by SDS-PAGE in 8% gel under reducing conditions, transferred to a nitrocellulose filter, and treated (or not) with 1 mU ml1' neuraminidase type V and with 0.25 ug ml-' of PNA. The lectin binding protein was visualised by autoradiography after incubating the filter with anti-PNA rabbit antibody (Accurate Chemicals and Scientific Corporation, Westbury, NY) followed by incubation in antirabbit I'25-labelled antibody (Amersham).
Results
The cultured cells from normal mammary gland stained strongly and specifically with PNA-FITC (Figure 1 ). Popula- .0
'a E E co ---;-11,-A C-,.. (Figure 4 , Table I ). This includes both established cell lines (D2A1, D2F2, EMT6RO8) and primary cultures of D2HAN derived tumours (Table I) . Because pretreatment with neuraminidase abolishes the differential binding of PNA by normal and transformed mammary cells (Table I) , differential sialylation rather than an absolute absence of PNA-specific oligosaccharides on the cell surface may be responsible. In many cases, however, the expression of tumorigenic potential seems to be associated with low PNA binding to mammary cells.
A single PNA reactive band (220 kd) common for normal, premalignant, and malignant mammary cells was observed ( Figure 9 ). Regardless of neuraminidase treatment, lysates of D2HAN derived tumours and BALB/cfC3H tumours did not exhibit the very large molecular weight band (> 250 kd) seen in D2HAN and normal mammary epithelium (arrow, Figure  9) It is well documented that abnormal expression of carbohydrates correlates with neoplasia (Feizi, 1985a) ; Hakomori, 1989) . Roles for both N-linked (Dennis & Laferte, 1989 and references therein) and 0-linked (Schirrmacher, 1982) oligosaccharides in invasion and metastasis have been postulated. Oncodevelopmental antigens have been detected in breast cancer specimens using monoclonal antibodies specific for blood group related carbohydrates (Feizi, 1985a; Feizi, 1985b; Gooi, 1985a; Gooi, 1985b) and PNA (Springer, 1984) . Sialylation of various glycoconjugates correlates with metastatic phenotype in different systems (Benedetto et al., 1989; Bresalier et al., 1990; Corfield et al., 1990; Friedman et al., 1988; Passaniti & Hart, 1988; Dennis et al., 1989) . However, there is also evidence indicating that in some systems the expression of non-sialylated structures binding SBA (Buckey et al., 1988) or PNA (Badenoch-Jones et al., 1987; Schirrmacher et al., 1982) is associated with metastasis. Sialylation of surface carbohydrates was alternatively correlated with cell proliferation (Kinoshita et al., 1989) or differentiation (Kinoshita et al., 1989; Kuratsu et al., 1990) . In some reports only subtle changes in glyconjugate expression patterns were seen between more and less malignant cell lines (Steck & Nicolson, 1983; Tresser & Nicholson, 1988) . Some studies suggest that sugar structures are directly involved in determination of cell phenotype due to modification of physical and/or biochemical properties of their surfaces (Dennis & Laferte, 1989; Friedman et al., 1988; Schirrmacher et al., 1982) . The importance of a particular structure seems to depend on the genetic background of cells expressing it. For example PNA receptor is normally expressed by human gastric mucosa of so called 'non-secretors' but is considered to be a tumour associated feature in 'secretors' (Feizi, 1985b) . Species specificity was also reported (Galili & Machmer, 1989) . On the other hand specific functions of some adhesion molecules, their ligands and other important known glycoconjugates were shown to be regulated by their glycosylation (Diamond et al., 1991; Larsen et al., 1990; Oz et al., 1989; Rabinovitz et al., 1991) .
Depite the plethora of information, which was only exemplified above, the clue for understanding the role of aberrant glycosylation in tumour progression seems still to be missing. The most common strategy in this area of research has been an analysis of paired cell populations usually representing a rather narrow 'window' of the whole process, for example a transition from low to high metastatic phenotype. We felt that because of the stepwise nature of tumour progression at the genetic level (Chen et al., 1989 and references therein) glycosylation changes may also follow a sequential course. This implies that initial conditions (differentiated phenotype) might be important. The expression of differentiation related carbohydrates recognisable by lectins was reported for several systems including hematopoietic cells (Reimann et al., 1984) , endothelium (Alroy et al., 1987) and mammary epithelium (Rudland, 1987) . The latter comprises several phenotypically distinct cell populations (Rudland, 1987; Sonnenberg et al., 1986) .
Interestingly, in rat and humans the main populations can be classified on the basis of their PNA binding patterns (Rudland, 1987; Newman et al., 1979) . In these studies ductal and alveolar cells bound the lectin with or without neuraminidase treatment, respectively. Myoepithelial and stromal cells were negative regardless of neuraminidase treatment. In the murine system we observed PNA binding sites widely distributed amongst mammary cell populations in culture (see Figure 1 ). Flow cytometry, however, clearly showed 20-fold lower PNA binding to stromal cells than to mammary epithelium (compare Figure 2) (Rak, Miller, unpublished Table I ) but we have not observed a metastatic and at the same time highly PNA binding mammary tumour. (iii) There was a loss of high molecular weight (conceivably mucin-like) PNA reactive glycoproteins (>250kd) during transition from hyperplasia to neoplasia; (iv) loss or hypersialylation of 90kd glycoprotein during development of neoplasia; and (v) hypersialylation of 150 kd glycoprotein in the case of highly tumorigenic but not in normal, preneoplastic and poorly tumorigenic D2.OR mammary cells. Recognition of these alterations leads to several further questions. First, do they represent consequences (markers) of tumour progression or are some of them necessary components of the malignant phenotype. Second, which component of a particular change is essential; the carbohydrate structure or the whole glycoprotein? Structural analysis of carbohydrates recognised by PNA (T-antigen and other terminal galactose-rich 0-linked structures) can be analysed by using a panel of monoclonal antibodies (Feizi, 1985; Hakomori, 1989) . We also intend to screen our material with antibodies recognising known molecules of corresponding size potentially involved in tumour progression. Mammary mucins (Taylor-Papadimitriou et al., 1990; McKenzie et al., 1990 ), E-cadherins (Nagafuchi et al., 1987) , CD44 (Brown et al., 1991) or betal integrin (Oz et al., 1989) are some of the obvious candidates. There is also an interesting size similarity between a sialylated gp 150 involved in liver metastasis formation by murine leukaemia cells (Benedetto et al., 1989) and the 150 kd glycoprotein sialylated during in vivo passage of mammary D2.OR tumour cells. Sialylation of the latter molecule appeared to be involved in full expression (or derepression?) of tumorigenicity. Interestingly, the highly tumorigeneic subclone (D2.1) and polyclonal populations (ET, Lg, Sm), all expressing the sialylated form of this glycoprotein (see Figure 7) , seem to be generated during interaction of the parental D2.OR clone with host environment since hypersialylation of that molecule occurred only after in vivo passage, but not during several months in culture. It is premature to speculate on mechanisms of this phenotypic switch in vivo until they can be reproduced by relevant in vitro systems. Both selection against high PNA binding variants and induction of the low PNA binding phenotype are conceivable. We are currently exploring a number of possibilities including tumour cell interaction with stromal cells, with extracellular matrix, and with the immune system. Thus, we have been able to demonstrate a series of sequential quantitative and qualitative changes in expression of PNA reactive glycoconjugates during murine mammary tumour development and progression. Further studies on the nature of those alterations and identity of molecules involved are currently being pursued. Hypersialylation of a 150kd glycoprotein seems to be important for host-dependent modulation of the tumorigenic phenotype of transformed mammary cells.
